Nkemdilim Clairelouise Okechukwu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Nkemdilim Clairelouise Okechukwu has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
Emmanuel Ogbonnia Ogudu
National Arbovirus and Vectors Research Centre, Enugu, Nigeria
2 shared publications- Ifeoma Esther Ani
Department of Medical Microbiology, Enugu State University Teaching Hospital, Parklane, Enugu, Nigeria
2 shared publications Theophilus Kachi Udeani
Department of Medical Laboratory Science, Faculty of Health Sciences University of Nigeria, Enugu Campus, Enugu, Nigeria
2 shared publications- Uzoma Chukwunonso Okechukwu
Department of Internal Medicine, Enugu State University Teaching Hospital, Parklane, Enugu, Nigeria
2 shared publications - Adebola Ayisat Effa
Department of Product Development and Quality Assurance, Nigeria Natural Medicine Development Agency, Lagos, Nigeria
1 shared publication - Aneke Emeka John
Department of Community Medicine, University of Nigeria Teaching Hospital, Ituku-Ozalla, Enugu, Nigeria
1 shared publication
Latest Publications
- Open Access
- 26 October 2026
- Published by Australasia Publishing Group in Epidemiology and Health Data Insights
- Vol. 2 (5) , ehdi060
Extended-Spectrum Beta-Lactamase-Producing Escherichia coli in Healthcare Settings: Epidemiology, Risk Factors, Infection Control Strategies and Emerging Treatment Options
Antimicrobial resistance continues to threaten the effectiveness of modern antimicrobial therapy, with ESBL-producing Escherichia coli emerging as a major cause of difficult-to-treat healthcare-associated infections. The global spread of these organisms is driven by antimicrobial selection pressure, genetic adaptability and transmission across healthcare, community and environmental reservoirs. This narrative review aimed to synthesise current evidence on the epidemiology, risk factors, transmission pathways, infection prevention strategies, antimicrobial stewardship approaches and emerging therapeutic options for ESBL-producing E. coli in healthcare settings. A structured narrative review was conducted using literature published between 2016 and the search date (June 6, 2026) indexed in PubMed, ScienceDirect, Dimensions and Google Scholar as well as literature obtained through grey literature search and screening of reference lists.. Relevant studies, including epidemiological investigations, molecular studies, clinical research, systematic reviews, surveillance reports and treatment guidelines, were critically analysed through thematic synthesis. The review found that ESBL-producing E. coli has become a globally distributed antimicrobial-resistant pathogen, with healthcare populations experiencing substantial intestinal carriage and infection burden. It was found that prolonged hospitalisation, previous antibiotic exposure, invasive devices, diabetes, chronic wounds and increased healthcare contact significantly contribute to colonisation and clinical infection. Furthermore, transmission is sustained through interactions between patients, healthcare workers, medical devices and contaminated environments. Antimicrobial stewardship, genomic surveillance, infection prevention measures and emerging therapies such as β-lactamase inhibitors, bacteriophage therapy and microbiome-based interventions represent important strategies for future control. Overall, reducing the burden of ESBL-producing E. coli requires coordinated global action integrating surveillance, responsible antimicrobial use, infection prevention and innovation in therapeutic development.
- 26 October 2026
- Published by Australasia Publishing Group in Epidemiology and Health Data Insights
- Vol. 2 (5) , ehdi060
Open AccessExtended-Spectrum Beta-Lactamase-Producing Escherichia coli in Healthcare Settings: Epidemiology, Risk Factors, Infection Control Strategies and Emerging Treatment Options
Antimicrobial resistance continues to threaten the effectiveness of modern antimicrobial therapy, with ESBL-producing Escherichia coli emerging as a major cause of difficult-to-treat healthcare-associated infections. The global spread of these organisms is driven by antimicrobial selection pressure, genetic adaptability and transmission across healthcare, community and environmental reservoirs. This narrative review aimed to synthesise current evidence on the epidemiology, risk factors, transmission pathways, infection prevention strategies, antimicrobial stewardship approaches and emerging therapeutic options for ESBL-producing E. coli in healthcare settings. A structured narrative review was conducted using literature published between 2016 and the search date (June 6, 2026) indexed in PubMed, ScienceDirect, Dimensions and Google Scholar as well as literature obtained through grey literature search and screening of reference lists.. Relevant studies, including epidemiological investigations, molecular studies, clinical research, systematic reviews, surveillance reports and treatment guidelines, were critically analysed through thematic synthesis. The review found that ESBL-producing E. coli has become a globally distributed antimicrobial-resistant pathogen, with healthcare populations experiencing substantial intestinal carriage and infection burden. It was found that prolonged hospitalisation, previous antibiotic exposure, invasive devices, diabetes, chronic wounds and increased healthcare contact significantly contribute to colonisation and clinical infection. Furthermore, transmission is sustained through interactions between patients, healthcare workers, medical devices and contaminated environments. Antimicrobial stewardship, genomic surveillance, infection prevention measures and emerging therapies such as β-lactamase inhibitors, bacteriophage therapy and microbiome-based interventions represent important strategies for future control. Overall, reducing the burden of ESBL-producing E. coli requires coordinated global action integrating surveillance, responsible antimicrobial use, infection prevention and innovation in therapeutic development.
- Open Access
- 30 September 2026
- Published by Australasia Publishing Group in International Journal of Evidence-Based Medicine
- Vol. 1 (3) , jebm015
The Hidden AMR Gap: A Scoping Review and AI Framework for Detecting Under-Surveillance of Antimicrobial Resistance
Background: Antimicrobial resistance (AMR) surveillance is essential for estimating resistance burden and guiding public-health responses, yet coverage remains uneven across geographic regions, populations, healthcare settings, and One Health domains. Low observed resistance may therefore reflect limited detection and reporting rather than genuinely low resistance. Objectives: To map the nature and determinants of AMR under-surveillance, examine computational approaches for identifying surveillance blind spots, and develop an evidence-informed framework for AI-enabled detection of hidden AMR surveillance gaps. Methods: PubMed and Dimensions were systematically searched for literature published from 2015–2026. Eligible studies addressed AMR surveillance coverage, capacity, representativeness, completeness, or computational approaches relevant to surveillance gaps. Study selection and synthesis followed JBI scoping-review methodology and PRISMA-ScR guidance. Results: Twenty-two studies were included. Under-surveillance encompassed geographic and population underrepresentation, diagnostic and laboratory limitations, fragmented information systems, delayed reporting, weak genomic coverage, and incomplete One Health integration. Computational approaches included spatial and statistical modelling, machine learning, geographic information systems, genomic analytics, digital laboratory systems, and environmental surveillance. These approaches could identify or partially address surveillance incompleteness but remained constrained by data quality and representativeness. The synthesis informed a framework for detecting discordance between expected AMR risk and observed surveillance intensity. Conclusions: AMR under-surveillance is a systems-level problem that can distort the apparent distribution of resistance. AI should complement microbiological surveillance by identifying uncertainty and prioritizing settings requiring strengthened surveillance.
- 30 September 2026
- Published by Australasia Publishing Group in International Journal of Evidence-Based Medicine
- Vol. 1 (3) , jebm015
Open AccessThe Hidden AMR Gap: A Scoping Review and AI Framework for Detecting Under-Surveillance of Antimicrobial Resistance
Background: Antimicrobial resistance (AMR) surveillance is essential for estimating resistance burden and guiding public-health responses, yet coverage remains uneven across geographic regions, populations, healthcare settings, and One Health domains. Low observed resistance may therefore reflect limited detection and reporting rather than genuinely low resistance. Objectives: To map the nature and determinants of AMR under-surveillance, examine computational approaches for identifying surveillance blind spots, and develop an evidence-informed framework for AI-enabled detection of hidden AMR surveillance gaps. Methods: PubMed and Dimensions were systematically searched for literature published from 2015–2026. Eligible studies addressed AMR surveillance coverage, capacity, representativeness, completeness, or computational approaches relevant to surveillance gaps. Study selection and synthesis followed JBI scoping-review methodology and PRISMA-ScR guidance. Results: Twenty-two studies were included. Under-surveillance encompassed geographic and population underrepresentation, diagnostic and laboratory limitations, fragmented information systems, delayed reporting, weak genomic coverage, and incomplete One Health integration. Computational approaches included spatial and statistical modelling, machine learning, geographic information systems, genomic analytics, digital laboratory systems, and environmental surveillance. These approaches could identify or partially address surveillance incompleteness but remained constrained by data quality and representativeness. The synthesis informed a framework for detecting discordance between expected AMR risk and observed surveillance intensity. Conclusions: AMR under-surveillance is a systems-level problem that can distort the apparent distribution of resistance. AI should complement microbiological surveillance by identifying uncertainty and prioritizing settings requiring strengthened surveillance.
- Open Access
- 11 September 2026
- Published by Sciencedomain International
- Vol. 9 (1) , 318-333
Prevalence, Antibiotic Resistance Patterns and Plasmid Mediated Resistance of Extended-spectrum Beta-lactamase Producing Escherichia coli Isolated from Long-term Hospitalized Patients
Antimicrobial resistance among healthcare-associated pathogens remains a major challenge, particularly among long-term hospitalised patients who are frequently exposed to antimicrobial therapy and healthcare environments. This study investigated the prevalence, antibiotic resistance patterns, plasmid profiles, and beta-lactamase resistance genes of extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli isolated from long-term hospitalised patients in selected tertiary hospitals in Enugu State, southeastern Nigeria. A hospital-based cross-sectional study was conducted among 204 patients hospitalised for 14 days or longer. Urine and wound samples were collected and analysed using standard microbiological procedures. E. coli isolates were identified by culture and biochemical methods, ESBL production was detected using Chromatic ESBL agar, antibiotic susceptibility testing was performed using the Kirby-Bauer disc diffusion method, and plasmid profiling and detection of blaTEM, blaSHV, and blaCTX-M genes were conducted using molecular techniques. Among the 204 clinical samples analysed, E. coli was isolated from 16/204 samples (7.8%), while ESBL-producing E. coli was detected in 10/204 samples (4.9%). ESBL-producing isolates were recovered mainly from urine samples (6/204, 2.9%) and diabetic wound ulcer samples (3/204, 1.5%). The E. coli isolates demonstrated high resistance to tested antibiotics, including complete resistance to several commonly used agents. Plasmid analysis showed that all 10 ESBL-producing isolates carried plasmids, while molecular analysis detected blaTEM in 10/10 isolates (100%) and blaCTX-M in 8/10 isolates (80%); blaSHV was not detected. The detection of plasmid-mediated ESBL-producing E. coli among long-term hospitalised patients highlights the need for continuous antimicrobial resistance surveillance, strengthened infection prevention practices, and effective antimicrobial stewardship programmes in healthcare facilities.
- 11 September 2026
- Published by Sciencedomain International
- Vol. 9 (1) , 318-333
Open AccessPrevalence, Antibiotic Resistance Patterns and Plasmid Mediated Resistance of Extended-spectrum Beta-lactamase Producing Escherichia coli Isolated from Long-term Hospitalized Patients
Antimicrobial resistance among healthcare-associated pathogens remains a major challenge, particularly among long-term hospitalised patients who are frequently exposed to antimicrobial therapy and healthcare environments. This study investigated the prevalence, antibiotic resistance patterns, plasmid profiles, and beta-lactamase resistance genes of extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli isolated from long-term hospitalised patients in selected tertiary hospitals in Enugu State, southeastern Nigeria. A hospital-based cross-sectional study was conducted among 204 patients hospitalised for 14 days or longer. Urine and wound samples were collected and analysed using standard microbiological procedures. E. coli isolates were identified by culture and biochemical methods, ESBL production was detected using Chromatic ESBL agar, antibiotic susceptibility testing was performed using the Kirby-Bauer disc diffusion method, and plasmid profiling and detection of blaTEM, blaSHV, and blaCTX-M genes were conducted using molecular techniques. Among the 204 clinical samples analysed, E. coli was isolated from 16/204 samples (7.8%), while ESBL-producing E. coli was detected in 10/204 samples (4.9%). ESBL-producing isolates were recovered mainly from urine samples (6/204, 2.9%) and diabetic wound ulcer samples (3/204, 1.5%). The E. coli isolates demonstrated high resistance to tested antibiotics, including complete resistance to several commonly used agents. Plasmid analysis showed that all 10 ESBL-producing isolates carried plasmids, while molecular analysis detected blaTEM in 10/10 isolates (100%) and blaCTX-M in 8/10 isolates (80%); blaSHV was not detected. The detection of plasmid-mediated ESBL-producing E. coli among long-term hospitalised patients highlights the need for continuous antimicrobial resistance surveillance, strengthened infection prevention practices, and effective antimicrobial stewardship programmes in healthcare facilities.
- 1 September 2026
- Published by IK Press in Journal of Advances in Food Science & Technology
- Vol. 13 (4) , 1-21
CRISPR and Next-generation Molecular Diagnostics for Foodborne Pathogen Detection: Analytical Performance, Matrix Robustness and Translational Readiness
Foodborne-pathogen testing increasingly requires results that are not only analytically sensitive but also rapid, interpretable, robust in heterogeneous matrices and compatible with decisions made across production, surveillance and outbreak response. Clustered regularly interspaced short palindromic repeats (CRISPR)-associated diagnostics have expanded this landscape by coupling programmable sequence recognition with collateral nucleic-acid cleavage, frequently after isothermal amplification. This critical narrative review evaluates CRISPR diagnostics alongside quantitative polymerase chain reaction, isothermal amplification, digital polymerase chain reaction, whole-genome sequencing and metagenomic or nanopore approaches, with emphasis on what determines performance in real food testing rather than purified-template experiments. Literature published from 1 January 2017 to 19 June 2026 was considered, with earlier foundational studies retained where necessary. The evidence indicates that Cas12a-centred assays can provide rapid and highly specific targeted detection across several bacterial and viral hazards, while Cas13, Cas12b, digital CRISPR and alternative readouts broaden the design space. Yet the apparent analytical gains are often contingent on upstream concentration, enrichment, lysis and amplification, and reported limits of detection are poorly comparable across studies because units, sample inputs, enrichment histories and positivity criteria differ. Viability discrimination, multiplexing, contamination control, reagent stability and prospective validation in naturally contaminated foods remain less mature than proof-of-concept sensitivity. Digital PCR offers stronger absolute quantification, whereas whole-genome sequencing and metagenomics provide strain resolution, source attribution and broader genomic context that targeted CRISPR assays cannot replace. The most defensible near-term model is therefore a tiered diagnostic architecture in which rapid CRISPR screening is integrated with fit-for-purpose sample preparation and linked to culture, quantitative molecular confirmation or sequencing according to the decision required. Translation will depend less on progressively lower nominal detection limits than on standardised validation of the complete sample-to-result workflow.
- 1 September 2026
- Published by IK Press in Journal of Advances in Food Science & Technology
- Vol. 13 (4) , 1-21
CRISPR and Next-generation Molecular Diagnostics for Foodborne Pathogen Detection: Analytical Performance, Matrix Robustness and Translational Readiness
Foodborne-pathogen testing increasingly requires results that are not only analytically sensitive but also rapid, interpretable, robust in heterogeneous matrices and compatible with decisions made across production, surveillance and outbreak response. Clustered regularly interspaced short palindromic repeats (CRISPR)-associated diagnostics have expanded this landscape by coupling programmable sequence recognition with collateral nucleic-acid cleavage, frequently after isothermal amplification. This critical narrative review evaluates CRISPR diagnostics alongside quantitative polymerase chain reaction, isothermal amplification, digital polymerase chain reaction, whole-genome sequencing and metagenomic or nanopore approaches, with emphasis on what determines performance in real food testing rather than purified-template experiments. Literature published from 1 January 2017 to 19 June 2026 was considered, with earlier foundational studies retained where necessary. The evidence indicates that Cas12a-centred assays can provide rapid and highly specific targeted detection across several bacterial and viral hazards, while Cas13, Cas12b, digital CRISPR and alternative readouts broaden the design space. Yet the apparent analytical gains are often contingent on upstream concentration, enrichment, lysis and amplification, and reported limits of detection are poorly comparable across studies because units, sample inputs, enrichment histories and positivity criteria differ. Viability discrimination, multiplexing, contamination control, reagent stability and prospective validation in naturally contaminated foods remain less mature than proof-of-concept sensitivity. Digital PCR offers stronger absolute quantification, whereas whole-genome sequencing and metagenomics provide strain resolution, source attribution and broader genomic context that targeted CRISPR assays cannot replace. The most defensible near-term model is therefore a tiered diagnostic architecture in which rapid CRISPR screening is integrated with fit-for-purpose sample preparation and linked to culture, quantitative molecular confirmation or sequencing according to the decision required. Translation will depend less on progressively lower nominal detection limits than on standardised validation of the complete sample-to-result workflow.
- 15 July 2026
- Published by Australasia Publishing Group in Australian Journal of Biomedical Research
- Vol. 2 (3) , aubm024
CRISPR-Cas9 in Human Health: A Scoping Review of Therapeutic Applications, Safety Challenges, and Ethical Frameworks
Background: CRISPR-Cas9 has revolutionized genome editing by providing an efficient, versatile, and comparatively accessible platform for targeted genetic modification. Its rapid progression from laboratory innovation to clinical application has generated substantial interest across multiple therapeutic domains, while simultaneously raising significant safety, ethical, and regulatory concerns. Objective: This scoping review aimed to comprehensively map current evidence regarding the therapeutic applications, safety challenges, and ethical frameworks associated with CRISPR-Cas9 in human health. Methods: A scoping review methodology guided by the Arksey and O’Malley framework and PRISMA-ScR guidelines was employed. Comprehensive searches were conducted across PubMed, Dimensions, and Embase for peer-reviewed English-language studies published between 2015 and 2026. Eligible studies focused on CRISPR-Cas9 applications in human health, including therapeutic interventions, safety evaluations, ethical analyses, and regulatory considerations. A total of 32 studies met the inclusion criteria and underwent thematic synthesis. Results: CRISPR-Cas9 demonstrated substantial therapeutic promise across hematologic disorders, metabolic diseases, ophthalmologic conditions, oncology, immunotherapy, and rare genetic disorders. The most clinically advanced applications were observed in sickle cell disease, β-thalassemia, hereditary transthyretin amyloidosis, and hereditary angioedema, where clinical trials showed durable and potentially curative outcomes. However, major barriers remain, including off-target effects, genomic instability, delivery inefficiencies, immunogenicity, and limited long-term safety data. Ethical and regulatory concerns were prominent, particularly regarding germline editing, health equity, global governance, and accessibility. Conclusion: CRISPR-Cas9 has demonstrated considerable clinical potential across a range of therapeutic applications, particularly for selected monogenic disorders in which the strongest clinical evidence is currently available. Although important advances have been achieved, broader clinical implementation will require continued improvements in editing precision, long-term safety evaluation, delivery technologies, ethical oversight, equitable access, and harmonized regulatory frameworks.
- 15 July 2026
- Published by Australasia Publishing Group in Australian Journal of Biomedical Research
- Vol. 2 (3) , aubm024
CRISPR-Cas9 in Human Health: A Scoping Review of Therapeutic Applications, Safety Challenges, and Ethical Frameworks
Background: CRISPR-Cas9 has revolutionized genome editing by providing an efficient, versatile, and comparatively accessible platform for targeted genetic modification. Its rapid progression from laboratory innovation to clinical application has generated substantial interest across multiple therapeutic domains, while simultaneously raising significant safety, ethical, and regulatory concerns. Objective: This scoping review aimed to comprehensively map current evidence regarding the therapeutic applications, safety challenges, and ethical frameworks associated with CRISPR-Cas9 in human health. Methods: A scoping review methodology guided by the Arksey and O’Malley framework and PRISMA-ScR guidelines was employed. Comprehensive searches were conducted across PubMed, Dimensions, and Embase for peer-reviewed English-language studies published between 2015 and 2026. Eligible studies focused on CRISPR-Cas9 applications in human health, including therapeutic interventions, safety evaluations, ethical analyses, and regulatory considerations. A total of 32 studies met the inclusion criteria and underwent thematic synthesis. Results: CRISPR-Cas9 demonstrated substantial therapeutic promise across hematologic disorders, metabolic diseases, ophthalmologic conditions, oncology, immunotherapy, and rare genetic disorders. The most clinically advanced applications were observed in sickle cell disease, β-thalassemia, hereditary transthyretin amyloidosis, and hereditary angioedema, where clinical trials showed durable and potentially curative outcomes. However, major barriers remain, including off-target effects, genomic instability, delivery inefficiencies, immunogenicity, and limited long-term safety data. Ethical and regulatory concerns were prominent, particularly regarding germline editing, health equity, global governance, and accessibility. Conclusion: CRISPR-Cas9 has demonstrated considerable clinical potential across a range of therapeutic applications, particularly for selected monogenic disorders in which the strongest clinical evidence is currently available. Although important advances have been achieved, broader clinical implementation will require continued improvements in editing precision, long-term safety evaluation, delivery technologies, ethical oversight, equitable access, and harmonized regulatory frameworks.
- 29 May 2026
- Published by IK Press in Journal of Disease and Global Health
- Vol. 19 (2) , 61-73
Tuberculosis and Rifampicin Resistance Trends in a Chest Hospital: A 3-Year Retrospective Study
Background: Multidrug-resistant tuberculosis warrants sustained monitoring of TB prevalence and rifampicin resistance to support disease control and patient management. Aim: This study evaluated the trend in tuberculosis and rifampicin resistance among suspected patients attending a chest hospital over a three-year period (2023-2025). Methodology: A retrospective descriptive hospital-based design was used. Laboratory records of suspected tuberculosis patients were reviewed, and only records with complete documented results were included. Extracted data included age, sex, tuberculosis test result and rifampicin resistance status detected using the GeneXpert MTB/RIF assay. Data were analysed using descriptive statistics, confidence intervals and Chi-square testing, with statistical significance set at p < 0.05. Results: Complete records for 4,508 suspected tuberculosis patients were reviewed. Of these, 811 patients (18.0%; 95% CI: 16.3-20.1) tested positive for tuberculosis, while 3,697 (82.0%) tested negative. Yearly tuberculosis positivity was 18.0% in 2023, 17.7% in 2024 and 18.2% in 2025, indicating a relatively stable pattern across the study period. Males had a slightly higher positivity rate than females, but tuberculosis positivity was not significantly associated with sex (χ² = 0.48, p = 0.489). Among the tuberculosis-positive patients, 766 (94.5%) were rifampicin-susceptible, 33 (4.1%) had indeterminate rifampicin resistance and 12 (1.5%; 95% CI: 0.8-2.6) were rifampicin-resistant. Confirmed rifampicin resistance remained low and showed no marked annual increase. Conclusion: Tuberculosis prevalence among suspected patients was stable during the three-year period, while confirmed rifampicin resistance was relatively low. Continued surveillance, timely diagnosis, treatment adherence and strengthened tuberculosis control remain important for limiting transmission and preventing further drug resistance.
- 29 May 2026
- Published by IK Press in Journal of Disease and Global Health
- Vol. 19 (2) , 61-73
Tuberculosis and Rifampicin Resistance Trends in a Chest Hospital: A 3-Year Retrospective Study
Background: Multidrug-resistant tuberculosis warrants sustained monitoring of TB prevalence and rifampicin resistance to support disease control and patient management. Aim: This study evaluated the trend in tuberculosis and rifampicin resistance among suspected patients attending a chest hospital over a three-year period (2023-2025). Methodology: A retrospective descriptive hospital-based design was used. Laboratory records of suspected tuberculosis patients were reviewed, and only records with complete documented results were included. Extracted data included age, sex, tuberculosis test result and rifampicin resistance status detected using the GeneXpert MTB/RIF assay. Data were analysed using descriptive statistics, confidence intervals and Chi-square testing, with statistical significance set at p < 0.05. Results: Complete records for 4,508 suspected tuberculosis patients were reviewed. Of these, 811 patients (18.0%; 95% CI: 16.3-20.1) tested positive for tuberculosis, while 3,697 (82.0%) tested negative. Yearly tuberculosis positivity was 18.0% in 2023, 17.7% in 2024 and 18.2% in 2025, indicating a relatively stable pattern across the study period. Males had a slightly higher positivity rate than females, but tuberculosis positivity was not significantly associated with sex (χ² = 0.48, p = 0.489). Among the tuberculosis-positive patients, 766 (94.5%) were rifampicin-susceptible, 33 (4.1%) had indeterminate rifampicin resistance and 12 (1.5%; 95% CI: 0.8-2.6) were rifampicin-resistant. Confirmed rifampicin resistance remained low and showed no marked annual increase. Conclusion: Tuberculosis prevalence among suspected patients was stable during the three-year period, while confirmed rifampicin resistance was relatively low. Continued surveillance, timely diagnosis, treatment adherence and strengthened tuberculosis control remain important for limiting transmission and preventing further drug resistance.